Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Do Not Miss the Eye in Acute Demyelinating Encephalomyelitis.
Single nucleotide polymorphisms with cis-regulatory effects on long non-coding transcripts in human primary monocytes.
cFLIP is critical for oligodendrocyte protection from inflammation.
[Registries for neurological drugs landscape].
Assessment of trace elements in human brain using inductively coupled plasma mass spectrometry.
[Current possibilities of the comprehensive diagnostic assessment in the differential diagnosis of inflammation and tumors of the spine cord.]
Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.
The neural androgen receptor: a therapeutic target for myelin repair in chronic demyelination.
Free light chain monomer-dimer patterns in the diagnosis of multiple sclerosis.
Oligodendroglia and neurotrophic factors in neurodegeneration.
A nexus between lipids and multiple sclerosis?
2010 McDonald criteria for diagnosing pediatric multiple sclerosis.
Telemedicine for Monitoring MS Activity and Progression.
Subgroup analysis in MS trials.
Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis.
Chondroitin sulfate β-1,4-N-acetylgalactosaminyltransferase-1 (ChGN-1) polymorphism: Association with progression of multiple sclerosis.
Three-dimensional geometries representing the retinal nerve fiber layer in multiple sclerosis, optic neuritis, and healthy eyes.
Alternative Approaches: A Systematic Review of Non-Pharmacological Treatments for Non-Spastic and Non-Trigeminal Pain in Patients with Multiple Sclerosis.
Hydrocephalus in neuromyelitis optica.
Marginal Structural Cox Models for Estimating the Association Between β-Interferon Exposure and Disease Progression in a Multiple Sclerosis Cohort.
Targeting of aquaporin 4 into lipid rafts and its biological significance.
A Voxel-based Morphometry Study of Grey Matter Volume Changes in Neuromyelitis Optica Patients.
Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability.
Natalizumab as a Disease-Modifying Therapy in Chronic Inflammatory Demyelinating Polyneuropathy - A Report of Three Cases.
Glial progenitor cell-based treatment and modeling of neurological disease.

Pages